Quanterix Corporation is a development stage diagnostics company utilizing proprietary Single Molecule Array (SiMoA™) technology for the development and commercialization of blood tests that measure clinically important proteins in blood. SiMoA, which is at least 1000-fold more sensitive than standard laboratory tests, will provide physicians and medical researchers with the tools to measure low abundance proteins. The application of SiMoA will lead to the development of a new generation of diagnostic tests, providing greater insight into disease detection, diagnosis and surveillance.

Doug Cole is on the Board of Directors.